valneva - Search News

News

FDA Suspends Valneva Vaccine's License

Valneva shares tumble after suspension of US chikungunya vaccine licence

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the licence for its chikungunya vaccine, Ixchiq, with immediate effect, citing serious safety concerns.

Fierce Pharma · 2d

FDA does a 180, suspending use of Valneva's chikungunya vaccine

· 2d

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

MedCity News1d

FDA Suspends Valneva Vaccine’s License Following New Reports of Adverse Events

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

BioPharma Dive2d

FDA suspends license for Valneva’s chikungunya shot

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

BioSpace2d

FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Jefferies lowers Valneva stock price target to $14 on FDA suspension

Investing.com - Jefferies has reduced its price target on Valneva SE (NASDAQ:VALN) to $14.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $9.13, Valneva has shown ...

TipRanks on MSN5d

Valneva SE (ADR) trading halted, news pending

SE (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results